All characteristic metabolic properties of a bio-fluid, cell, tissue or an organism are described by its metabolome, which is the functional readout of the genome and proteome. Metabolomics is the newest member in the omics cascade investigating the metabolome within a specific biological matrix (e.g. serum, tissue, cells or CSF) offering the possibility of assessing the relationship of a genetic modification to a specific desired phenotype in an effort to determine the critical biochemical pathways involved. Today the emerging technology of (targeted) metabolomics contributes extremely successful in new insights of metabolic phenotyping (metabotypes) and as a logical consequence in improved metabolic understanding of complex diseases and related biomarker discovery (e.g. metabolic disorders, oncology, cardiovascular diseases) for disease development, progression, treatment, and drug function and assessment. Over 600 metabolites can be identified, quantified easily and quality controlled on a newly developed metabolomics platform and kits with high reproducibility and accuracy. The set of analytes consists of the following classes i.e. acylcarnitines, amino acids, biogenic amines, eicosanoids, lipids, steroids, neurotransmitters, bile acids, energy metabolism, and oxysterols, in which the appropriate pathways are partly linked to androgens. The developed metabolomics platform and kits products represents a powerful tool for the standardized metabolome analysis allowing a global interlaboratory comparibility of the sample and sample data analysis for more than 20 different tested biological matrices in more than 15 different species. Current metabolic biomarker studies covering different application areas will be presented underlying the power and clinical future of metabolome analysis.
Presenting Author: Therese Koal, BIOCRATES Life Sciences AG, Eduard-Bodem-Gasse 8, A-6020 Innsbruck, Austria. Email: email@example.com